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Introduction
In the recent South African Stress and Health Study (SASH), 
the first large-scale, nationally conducted population-based 
survey of mental disorders, the population prevalence of 
panic disorder (PD) was estimated to be approximately 
1.2%.1 Although this was somewhat lower than international 
estimates,2,3 PD was also found to be the anxiety disorder 
that was most commonly associated with severe symptoms 
and functional impairment. Adults who were older than 35 
years bore the largest burden of disease. Females were at 
greater risk than males.
PD is a chronic condition that often follows an intermittent 
course. Over time, there are relapses and remissions.4-6 It 
is characterised by the recurrence of unexpected panic 
attacks, which are then often followed by anticipatory 
concern. Typically, the age of onset of this disorder is late 
adolescence to the mid-30s.7
Pathogenesis of panic disorder
The pathophysiology of PD is multifactorial. There is strong 
evidence of familial aggregation. First-degree relatives are 
more liable to develop PD than the general population.8-11 
The majority of this familial risk is thought to be conferred 
by genetic factors. Twin studies have strengthened the case 
for genes, rather than for common family environments, in 
predicting PD, as evidenced by the higher concordance 
in monozygotic twins vs. dizygotic twins.12,13 According to 
the “equal environments assumption”,8 monozygotic intra-
pair correlation is more strongly attributable to genetic 
resemblance, rather than to environmental similarities. That 
being said, individual specific environmental conditioning, 
such as early parental separation or childhood trauma, may 
also contribute to varying liability to PD.8,14-17
It has also been suggested that neurobiological 
abnormalities in regions such as the medial prefrontal 
cortex, brainstem and limbic system (including the temporal 
lobe, amygdala and hippocampus) mediate PD.14,18-20 This is 
in line with the current understanding of the neurocircuitry 
of fear, in which the amygdala facilitates the processing of 
sensory input from the cortex to efferent target organs.14 
The role of neurochemical and molecular derangements 
in these pathways is also increasingly understood. The 
serotonergic,21 noradrenergic22 and neuropeptidergic23,24 
systems have been found to be particularly important in 
the mediation of PD and have been the targets of major 
treatment strategies.
Single-gene polymorphisms in these classic neurotrans-
mitter systems have also been the subject of recent work. 
For example, variations in the monoamine oxidase A,25 
catechol-O-methyltransferase26 and cholecystokinin B 
receptor23 genes have shown associations with PD. However, 
these findings have not been consistently replicated and no 
specific susceptibility loci have been established.27-29 Thus, 
a genome-wide association approach is increasingly being 
used to delineate such loci.30,31 Additional, genome-wide 
association studies in larger population samples, as well 
as gene-environment interaction studies, are needed to 
confirm preliminary results.
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Abstract
Panic disorder (PD) is an anxiety disorder that affects many South Africans. If undiagnosed or mismanaged, this condition 
may impact profoundly on an individual’s functioning and quality of life. At the primary level, the assessment of panic 
attacks requires consideration of a number of differential diagnoses. General practitioners also play an invaluable role in the 
acute and long-term care and appropriate referral of individuals with PD.  This article provides an overview of PD in general 
practice and includes a guideline for case identification and therapeutic options.
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Diagnosing and assessing panic disorder 
in general practice
In many cases, the diagnosis of PD is likely to be the 
responsibility of the general practitioner. Access to specialist 
psychiatric care is limited for most South Africans, so 
primary care practitioners should be equipped to identify 
and manage such cases.32 According to the proposed 
Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM-V) diagnostic criteria6 (Table I), the hallmark 
clinical feature of PD is the recurrent, unexpected panic 
attack. These attacks are characterised by a sudden surge 
of intense fear or discomfort, the severity of which usually 
peaks within minutes.33 Symptoms of a panic attack include 
cardiovascular, e.g. chest pain and palpitations; respiratory, 
e.g. shortness of breath and choking sensations; 
gastrointestinal, e.g. nausea; neurological, e.g. dizziness 
and paraesthesias; autonomic, e.g. sweating, trembling, 
chills and heat sensations; and psychiatric features, e.g. 
derealisation, depersonalisation, fear of dying, losing 
control and going “mad”. For a definitive diagnosis, four 
or more of these symptoms should be present.33 These 
attacks are then followed by persistent anxiety about future 
attacks, with resultant behaviour changes, e.g. avoidance 
of settings or situations thought to be associated with such 
attacks (Table I).  While it has been suggested that the 
heterogeneity of PD warrants categorisation into distinct 
subtypes, e.g. respiratory, nocturnal, non-fearful, cognitive 
and vestibular, further work is needed before this subtyping 
is widely implemented in clinical practice.34
The clinical presentation of PD is highly heterogenous. In 
fact, individuals are more likely to complain of physical 
symptoms which they attribute to general medical 
conditions, rather than correctly identifying a panic attack.35 
Respiratory illnesses are of particular interest in persons 
with PD, and their association has often been explained by 
Klein’s “false suffocation alarm”.36 This theory posits that 
locus coeruleus hyperactivity in individuals with PD leads 
to a hypersensitivity to subtle increases in arterial carbon 
dioxide. These increases are misperceived as a state of 
asphyxia and result in inappropriate hyperventilation. As 
obstructive pulmonary disease is often also associated with 
intermittent hypercapnia, these individuals are at increased 
risk of hyperventilation and panic.7,37 This may explain the 
overlapping symptomatology and high rate of co-morbidity 
between PD and asthma/chronic obstructive pulmonary 
disease.38-40
Once a panic attack has been correctly diagnosed, it is 
important to ascertain whether this feature is a component 
of PD, or some other anxiety or non-anxiety disorder.33 
While a necessary feature of PD, panic attacks alone are not 
sufficient to diagnose this disorder, as they may manifest in 
a variety of clinical scenarios. For example, panic attacks 
that are limited to particular situations are more likely to 
be a symptom of social anxiety disorder (if these occur 
when individuals are forced into social interactions), or 
of a specific phobia (if these occur when individuals are 
exposed to phobic stimuli, e.g. heights or receiving an 
injection).6,7 Similarly, if the attacks occur only when the 
person is reminded of a recent trauma, a diagnosis of post-
traumatic stress disorder is most likely. If the symptoms 
are associated with obsessive thoughts and occur in 
conjunction with repetitive, time-consuming compulsive 
behaviours, the person should be assessed for obsessive-
compulsive disorder.6 By contrast, panic attacks that are 
not bound to the situation, and which instead occur in a 
range of varied and unexpected settings, may signify a PD 
diagnosis.
The frequency and intensity of attacks should also be 
elicited in order to determine the degree of functional 
impairment that is experienced by the individual. Typically, 
individuals with PD exhibit maladaptive behaviour changes, 
which in their most severe form, may result in agoraphobic 
avoidance of a variety of commonplace situations, e.g. 
crowds, open spaces and public transportation.41
Persons with PD are also more at risk of suffering from 
a range of co-morbidities.2 For example, PD and major 
depression have been found to be significantly interrelated.2 
From a clinical perspective, this co-occurrence has 
Table I: Proposed DSM-V diagnostic criteria for panic disorder
A. Recurrent, unexpected panic attacks.
B. At least one of the attacks has been followed by one month (or more) of one or both of the following:
1. Persistent concern or worry about additional panic attacks or their consequences, e.g. losing control, having a heart attack or “going crazy”. 
2. Significant maladaptive change in behaviour that relate to the attacks, e.g. behaviours designed to avoid having panic attacks, such as 
avoidance of exercise or unfamiliar situations.
C. The disturbance is not attributable to the direct physiological effects of a substance, e.g. a drug of abuse, a medication or another medical 
condition, e.g. hyperthyroidism and cardiopulmonary disorders.
D. The disturbance is not better accounted for by another mental disorder, e.g. the panic attacks do not occur only in response to feared social 
situations (in social anxiety disorder), circumscribed phobic objects or situations (in specific phobia), obsessions (in obsessive-compulsive 
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important prognostic implications as individuals with 
PD and co-morbid major depression often experience 
increased symptom severity (with augmented suicide risk), 
a higher degree of functional impairment and poorer long-
term treatment response.7,42
Overall, individuals with PD tend to be high utilisers of 
primary healthcare services.43 This may be because of 
hypersensitivity to severe symptoms or misattribution 
of these symptoms to acute medical illness.7,44 Thus, 
misdiagnosis or inappropriate management of PD at the 
primary level can have far-reaching consequences, not 
only for the individual and his or her family, but also for the 
healthcare system as a whole.
Guidelines for management
Acute treatment
In the acute setting, a number of pharmacological or 
psychological treatments have proven effective in persons 
with PD. Ultimately, management should be individualised 
and based on personal preference, co-morbidities, 
previous treatment response and tolerability.45-47 First-line 
pharmacological agents include the selective serotonin 
reuptake inhibitors (SSRIs) and serotonin-noradrenaline 
reuptake inhibitors (SNRIs), both of which also have 
antidepressant efficacy. While fluoxetine,48,49 sertraline,50,51 
paroxetine,52 and the SNRI, venlafaxine,53,54 have been most 
rigorously investigated, there seems to be little difference in 
efficacy within and between these drug classes.55
As a general rule, the chosen pharmacotherapeutic agent 
should be started at very low dose. Individuals with PD have 
been found to be particularly sensitive to the side-effects of 
drug therapy and may even mistake adverse effects such as 
dizziness, tremor and tachycardia for the physical symptoms 
of a panic attack.56 Thus, to encourage treatment adherence, 
it is important to prepare patients for the occurrence 
of side-effects, e.g. gastrointestinal disturbances, anti-
cholinergic effects and sexual disturbance, which are 
usually common during treatment initiation. Although some 
symptom improvement may be evident within a week of 
starting treatment, an acute trial should be undertaken for 
approximately six to eight weeks.46,57 During this time, drug 
dosage should be increased incrementally, e.g. one- to two-
weekly, until the therapeutic range is reached.46
In the short-term, adjunctive benzodiazepines, e.g. 
clonazepam treatment, may also be helpful in hastening 
treatment response, particularly in the case of severe 
symptoms.58,59 However, given their unfavourable side-
effect profile and associated problems of dependence and 
rebound anxiety,60,61 benzodiazepines should not be used 
as first-line monotherapy for persons with PD.45-47
Of the nonpharmacological treatment options, cognitive- 
behavioural therapy (CBT) has consistenly been found 
to be the most effective.62,63 Generally, key components 
include psycho-education, cognitive strategies and 
exposure or desensitisation therapy.46,64 At the primary 
level, general practitioners may certainly implement 
simple psychotherapeutic interventions, such as providing 
information about PD to individuals and their families and 
encouraging exposure to, rather than avoidance of, feared 
stimuli. There is surprisingly little evidence in favour of 
the combined use of pharmaco- and psychotherapeutic 
interventions in the treatment of PD,45 although from 
a theoretical perspective, it may be useful to adopt a 
sequential approach, as medication has a faster onset and 
CBT facilitates a more sustained response.
Long-term treatment
When the individual has demonstrated a satisfactory 
response to acute treatment, pharmacotherapy should be 
continued for at least 8-12 months.46,65 Once the decision 
has been made to discontinue treatment, this should be 
carried out gradually, over a period of at least eight weeks, 
in order to minimise the risk of rebound anxiety.46 It has 
been found that supplemental CBT, offered at the time of 
treatment withdrawal, has lowered relapse rates in some 
people.66,67
In the long term, most treatment guidelines advocate a 
collaborative approach between patient and healthcare 
provider to optimise management. As this chronic disease 
often features intermittent relapse-remission cycles, the 
general practitioner should strive to empower individuals to 
take responsibility for the day-to-day management of their 
condition. Thus, persons with PD should be encouraged to 
take a proactive role in adhering to prescribed treatments, 
adopting improved lifestyle habits and coping strategies and 
monitoring their responses to therapeutic interventions.3 
Self-rating symptom scales may be useful in this regard. For 
example, the Panic and Agoraphobia Scale68 and the Panic 
Disorder Severity Scale69 may be used by individuals to 
monitor their own symptom severity, functional impairment 
and treatment response.
Treatment of non-responders
The primary level approach to the individual who does not 
respond adequately to first-line treatment should begin 
with a critical evaluation of the initial diagnosis of PD, the 
presence of co-morbidities that may have been overlooked, 
whether or not he or she is adherent to the prescribed 
treatment (paying particular attention to troublesome side-
effects)70 and whether or not a therapeutic trial of appropriate 
dose and duration has been undertaken.
Once a case of treatment non-response has been 
established (defined as a failure to achieve at least 50% 
symptom reduction, as measured by a standard rating scale 
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dosage),71 consideration should be given to switching to 
a different first-line agent. As there is no clear evidence to 
support dose escalation in treatment of non-responders,45 a 
switch strategy should be the next step at the primary level.
However, should this also prove to be unsuccessful, the 
general practitioner should consider referring the patient 
to a specialist psychiatrist for the initiation of second-line 
therapy. Suitable second-line agents include the tricyclic 
antidepressants, e.g. clomipramine and imipramine,72 and 
benzodiazepines, e.g. alprazolam and clonazepam.73,74
Augmentation strategies may also be helpful in treating 
non-responders. Third-line agents which may be suitable as 
adjuncts include atypical antipsychotics. e.g. olanzapine.75 
However, as the tolerability and potential drug interactions 
of these agents are more problematic than the SSRIs, 
referral to more specialised psychiatric care is warranted. 
Some guidelines also suggest the use of adjunctive CBT 
in individuals who have failed to respond adequately to 
pharmacotherapy.45,46 Group CBT, in particular, has been 
found to be effective in some cases.76,77
When to refer to psychiatric services
As discussed, the general practitioner should consider 
referral of those who have failed to respond to first-line 
treatment. Additional high-risk subgroups that warrant 
specialised psychiatric evaluation include children and 
adolescents, the elderly, pregnant women and highly co-
morbid individuals, particularly those with severe major 
depression or active suicidality.45
Special populations
Children and adolescents
While initially conceptualised as a disorder that occurs 
exclusively in adulthood, it is now recognised that a 
significant proportion of adults with PD report the onset 
of symptoms before the age of 18.78 PD in childhood and 
adolescence is often disabling and may be associated 
with a range of psychological, social and school-related 
impairments.79 Risk factors include cognitive-affective 
sensitivity, e.g. negative affectivity;80 environmental 
stress, e.g. family conflict;81 and heritable factors, e.g. a 
family history of PD.82,83 While the clinical presentation 
is similar to that of adults with the disorder, paediatric 
presentations are often complicated by an exceptionally 
high rate of co-morbidity with other anxiety disorders or 
major depression.84,85As is the case in adults, SSRIs appear 
to be the mainstay of pharmacotherapy in paediatric 
cases.45 However, empirical evidence for this is sparse, and 
arguably, nonpharmacological interventions should be the 
first-line option in children and adolescents. Generally, age-
appropriate psycho-education of the individual and his or 
her family and psychological therapy should be employed 
by a specialist healthcare provider.45,46
The elderly
Although agoraphobia in the elderly may be relatively 
common,86 PD in persons over the age of 65 is not.1 
Nonetheless, the general practitioner should be prepared 
to manage the complexities of such cases. Deteriorating 
physical, cognitive and psychological functioning may 
worsen prognosis and impair treatment response. 
Furthermore, high rates of co-morbid medical disorders 
and polypharmacy may complicate treatment. As there is a 
paucity of evidence for the management of PD in the elderly, 
most guidelines suggest following the recommendations 
that are provided for younger adults, while remaining 
cognisant of these particular challenges.
Conclusion
PD is a common disorder that often presents in medical 
settings and that may lead to high healthcare utilisation. 
In South Africa, the general practitioner is ideally placed 
to identify individuals with this disorder, to implement 
appropriate interventions and to refer to more specialised 
psychiatric services when necessary. Fortunately, in 
most cases, persons with panic disorder respond to first-
line, easy-to-use interventions, many of which may be 
implemented in general practice.
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